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Abstract 
 As the occurrence of breast cancer increases around the world, the need for new 
therapeutic medicine becomes more vital to sustain the population. In order to accomplish this, 
specific mechanisms need to be understood to gain a perspective on the overall process of breast 
cancer development. One mechanism that is being researched is SUMOylation. The 
SUMOylation reaction uses small ubiquitin-like modifier (SUMO) proteins, which act as a type 
of post-translational modification that is necessary in order to preserve protein homeostasis and 
regulate cellular processes including apoptosis, cell proliferation, and response to stress. The 
SUMOs attach to a target protein through a SUMO E3 ligase and the modified protein then gains 
different cellular functions. An example of the SUMO-mediated protein degradation involves 
Arkadia, a SUMO-targeted ubiquitin ligase, which stimulates the degradation of the Ski protein, 
which is associated with tumor growth and development. 
   Breast Cancer Associated Gene 2 or BCA2 is identified as an E3 ligase in the ubiquitin 
proteasome system.  It has been found that BCA2 is co-expressed with the estrogen receptor 
(ER) in ER-positive breast cancer cells.  ER is crucial in the regulation of cell cycle progression 
and growth of breast cancer epithelial cells. Previous studies have shown that the BCA2 gene is 
regulated by the ER and BCA2 protein interacts with UBC9 and E2 ligase in the SUMOylation 
pathway. The regulation of BCA2 could prove critical since it could mediate the ubiquitination 
and possible SUMOylation of target proteins. While BCA2 as an Ubiquitin E3 ligase has been 
well established, its role in SUMOylation is unknown. The aim of this thesis is to identify 
BCA2’s involvement in SUMOylation. To achieve this, I performed bioinformatics analysis of 
the BCA2  protein sequence and found that out of the 6 lysines (Ks) in the sequence, K32 is the 
possible lysine important for SUMO attachment. I also tested the SUMOylation of BCA2 in an 
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in vitro assay by using SUMO-specific proteins. The results have revealed an association 
between SUMO 2/3 and BCA2. Plasmids containing SUMO 1 and 2/3 were then purified from 
Top10 bacterial cultures and were transfected into HEK293 cells for immunoprecipitation 
experiments. Preliminary data from these experiments reveal a possible interaction of BCA2 
with SUMO2/3. The involvement of BCA2 in both ubiquitination and SUMOylation pathways 
as an E3 ligase makes it a novel target for therapeutic intervention for the prevention and 
treatment of breast cancer patients. 
 
Introduction 
 Cancer is a disease that has become increasingly prevalent in the world population in the 
recent years and is predicted to continue to be the second most common cause of death in the 
United States. In fact, according to the American Cancer Society, 1,660,290  new cancer cases 
are expected to be identified, while 580,350 Americans are expected to die of cancer in this year 
alone [1]. Worldwide, it is predicted that by 2020, the world population will be 7.5 billion and 15 
million new cancer cases will be diagnosed [2]. Because of this constant increasing 
predominance, it is vital to learn how cancer cells function in the human body in order to develop 
new and more effective treatment options. This life-changing disease results from an 
uncontrolled growth of transformed human cells, which are thus called cancerous cells. Under 
normal conditions, cells are regulated with immense precision and accuracy by signals released 
by the body's tissues. When cells have served their purpose or have become old, the body 
efficiently removes them from the system either by apoptosis or by phagocytic cells in a process 
called efferocytosis [3]. When a tissue is damaged, normal cells grow until the tissue is 
completely healed. However, in cancer, these seemingly normal human cells continue to divide 
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at an undisciplined rate until a tumor is formed that could then metastasize and move to other 
organ systems to spread the disease. Though many causes of cancer may be uncontrollable, it is 
also caused by lifestyle preferences that people could change, including smoking, diet, exercise, 
and obesity, in addition to others [4].  
 Since each tissue and organ in the human body is composed of cells, essentially every 
part of the body is susceptible to cancer. As a result, many forms of cancer arise with each organ 
that is affected. One type of cancer that is becoming progressively more widespread is breast 
cancer. According to U.S. National Library of Medicine, 1 in 8 women will be diagnosed with 
this type of cancer during their lifetime [5]. Additionally, the American Cancer Society states 
that breast cancer is the most common cancer among women in the United States, excluding skin 
cancer [6]. For this reason, it is crucial to continue research in order to facilitate the discovery of 
new drugs and treatment options.  
 One strategy for improving breast cancer treatment is to explore the mechanisms of 
protein molecules that affect growth and proliferation of breast cancer cells and their regulations. 
Cellular homeostasis is necessary in order to maintain cell function and regulation. For this 
reason, many of the cellular processes that are vital to a cell, such as apoptosis and transcription, 
are highly controlled with specific proteins preserving the different mechanisms and occurrences 
of a functional cell. These proteins and molecules are, themselves, kept in check by various other 
molecules so that no single molecule has complete control of the cell and its interactions. This 
allows the numerous proteins to work in conjunction with one another in order to keep the cell 
check-and-balanced and its proliferation rate regulated so that cells do not continue dividing 
ungoverned and do not become cancerous within the body's tissues.  
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 One such vital regulatory protein that is found in most eukaryotic organisms is ubiquitin 
[7]. This highly conserved protein can attach to various proteins and direct them to the 
proteasome for degradation in an enzymatic process called ubiquitination [8]. Since this protein 
decides which proteins are still needed by the cell and which proteins can be discarded, ubiquitin 
is necessary to maintain the customary functions of a eukaryotic cell and a defect in this process 
can cause many diseases, including cancer [9]. In fact, ubiquitin is essential in protein 
modification and protein turnover, as well as the balance between synthesis and degradation of 
proteins, making this protein a necessity for functional cells [10, 11,12]. Ubiquitin marks a 
protein for degradation with three steps. First, the protein is activated by an ubiquitin-activating 
enzyme (E1); next the ubiquitin is transferred from the E1 to an ubiquitin-conjugating enzyme 
(E2); finally, the conjugating E2 enzyme is added to the target protein by an ubiquitin ligase (E3) 
[13]. The E3 ubiquitin ligases are known to play a role in cell proliferation, apoptosis, and cancer 
invasion [13]. Ubiquitin E3 ligases allow substrates to bind to the ubiquitin-proteasome complex 
for degradation. There are two domains an E3 ligase can contain: a HECT domain and a RING 
domain [14]. Therefore, E3 ligases are found to be a therapeutic target since its deregulation is 
known to be a part of the proliferative diseases [15].   
An E3 ligase with a RING domain is Breast Cancer Associated Gene 2 or BCA2 [16]. 
This protein, which was identified by hybridization cloning of cDNA using normal and 
cancerous breast cells [17], is known to be expressed in breast cancer cell lines [16]. In addition 
to a RING domain which is vital for its autoubiquitination, BCA2 also has a zinc finger domain.  
BCA2 is expressed in primary invasive breast cancers and is associated with a positive 
estrogen receptor status [15, 18]. As shown in Table 1 of ref. [17], BCA2 is expressed in 74% of 
ER-positive invasive breast cancers. Estrogen regulates the proliferation and development of 
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tissues that express ER and therefore, estrogen and ER can be a risk factor for breast cancer 
development [16]. It has been shown that BCA2 is a target of ER transcriptional activity in ER-
positive breast cancer cells and that the BCA2 gene is up-regulated with more of the hormone 
[19].  
It has been proposed that BCA2 may be involved in the attachment of SUMO proteins 
[16]. SUMOylation is a type of post-translational modification that is involved in many cellular 
processes including transcriptional regulation, apoptosis, protein stability, and cell cycle 
progression [20]. The SUMOylation reaction uses small ubiquitin-related modifier (SUMO) 
proteins, which bind to the substrate protein with the help of E3 ligases, targeting them for either 
degradation or other cellular functions [16]. ER has SUMO-attachment sites and is activated 
when it undergoes SUMOylation [21]. Since ER is highly expressed in breast cancer patients, 
along with BCA2, SUMOylation of BCA2 needs to be studied further in order to better 
understand its role in breast cancer and if it can be a potential target for treatment options.  
Furthermore, it has been shown that RING-E3 ligases are important in the SUMO 
pathway, since they stabilize proteins and compete for ubiquitin modification sites [22]. As a 
result, BCA2, as a RING-E3 ligase, interacts with Ubc9, an E2 enzyme in the SUMO pathway 
[16], which was discovered from pull down and immunoflourescence assays [17]. Additionally, it 
was observed that co-localization occurs between these two proteins in both the nucleus and the 
cytoplasm [17]. Therefore, BCA2 could act as an E3 component of the SUMOylation process 
and the regulation of this protein could prove a pivotal target for treatment options. In order to 
fully understand the involvement of BCA2 in the SUMOylation process, I have studied 
SUMOylation of BCA2 in vitro using SUMO- proteins and researched the role of BCA2 in 
SUMOylation. 
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Materials and Methods 
 In order to conduct experiments regarding SUMOylation of BCA2, the following 
materials and methods were used.  
Cell Lines 
Cells were originally purchased from the American Type Culture Collection. They 
include the BCA2-expressing breast cancer cell MCF-7 and HEK293. The cell lines were 
cultured in RPMI 1640 or DMEM media, which was supplemented with 10% Fetal Bovine 
Serum (FBS) and grown under standard conditions at 37ºC and 5% CO2.  
Recombinant BCA2 
Human BCA2 encoding DNA was cloned into the pET100 expression vector (Invitrogen) 
and used in in vitro SUMOylation experiments. An expression vector is used to introduce a gene 
to a specific target in order for the target cell to stimulate protein synthesis of the protein 
encoded by the gene. The recombinant protein was purified by affinity chromatography using the 
ProBand Purification System from Invitrogen.  
Sumoylation Assay and Western Blotting 
 Recombinant BCA2 produced from E.Coli was used for SUMOylation experiments by 
adding ATP (Sigma-Aldrich), Sumo 1 or 2/3 (Sigma-Aldrich), E1, and E2/Ubc9 in Tris•HCl, pH 
8.0. The reagents were mixed with 10X reaction buffer and water for an incubation period of two 
hours at 30ºC under constant shaking in a shaking incubator running at 250 rpm. The reactions 
were separated on a SDS-PAGE Gel and then transferred to a membrane, where it was subjected 
to immunoblotting with anti-Sumo 1 and 2/3 antibodies. Immunoblotting is a technique that uses 
antibodies to identify the target protein through antibody-antigen interactions.  
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 Also, the proteins from treated cells were then separated on 4-20% SDS-PAGE Gels 
(Invitrogen) and transferred to PVDF/nitrocellulose membranes. Primary antibodies were diluted 
in blocking buffer and incubated for one hour at room temperature. The membranes were then 
incubated with species-specific secondary antibodies conjugated to horseradish peroxidase for 
one hour. Signals were developed using a chemiluminescence kit (Millipore) and detected using 
a FOTODYNE Gel Doc system.  
Immunoflourescence 
 Cells were added in 8-well chamber slides (30,000/well) and were allowed to grow to a 
maximal amount of 80% and then rinsed with Phosphate-Buffered Saline (PBS) and fixed with 
an ice cold methanol:acetone (1:1) mixture and air dried for fifteen minutes.  Slides were then re-
hydrated in PBS, followed by a one hour blocking of unspecific binding sites in 5% Bovine 
Serum Albumin (BSA)/PBS.  For dual labeling, slides were incubated for two hours with a 
mixture of polyclonal and monoclonal antibody and developed with species-specific 
FITC/TRITC secondary antibodies. FITC/TRITC are isothicyanates that are used for protein 
fluorescent labeling. Nuclei were counterstained with DAPI, a fluorescent stain, for three 
minutes. 
Plasmid Preparation 
Transforming Plasmid DNA 
 Transformation is a way in which cells take up DNA molecules, and it can be 
replicated along with the cell’s own DNA. This involves competent cells that can uptake 
DNA from their surroundings. 
 
Antibiotic Selection 
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 Not all of the competent cells will uptake the DNA; if they do, it does not 
necessarily mean the cells will transfer the DNA to its descendent cells.  Therefore, in 
order to find out which cells contain the DNA plasmid, antibiotic selection is applied. 
This process includes growing the cells on antibiotic resistant agar plates, such as 
kanamycin or ampicillin. Cells with successfully transformed plasmids will be resistant to 
the antibiotic and be able to grow on the plate. These cells will form colonies, a visible 
cluster of growth on the plate originating from a singular cell that has procreated 
numerous times while in the incubation period.  
 
Growth of single colony in Lysogeny Broth (LB) Broth 
 Among the colonies that have successfully grown, one is picked for further study. 
This colony is placed in LB Broth medium along with the antibiotic and allowed to grow 
overnight on a shaking incubator.  
 
Cell Pellets 
 The single colony grown in LB broth is then isolated from the medium and the 
cells pelleted using centrifugation. Since the collection of cells is more dense then the 
medium, the cells collect in a white group at the bottom of the tube with the broth on top.  
 
Plasmid Purification 
 Plasmid purification is a way to isolate and purify plasmid DNA. This preparation 
method depends on the size of the plasmid DNA.  The one I used was Minipreparation, 
which is for small-scale plasmid DNA. This process included adding many buffers in 
order to wash the DNA and obtain the maximum yield.  
 
NanoDrop  
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 After purifying the plasmid, the DNA concentration is measured using the 
NanoDrop machine. This measures the quality and concentration of the DNA in the 
sample so that it can be compared to different strains and be used for further experiments. 
 
Agarose Gel Electrophoresis 
 After obtaining the DNA concentration, an agarose gel is run in order to visually 
see the DNA and determine its weight in comparison to a DNA ladder, which is a 
solution of DNA molecules of varying lengths used as a reference to get an estimation of 
the size of the unknown DNA molecules from the sample cells. The one I used had the 
length of 1 kb. After making the gel and applying the various samples into the wells, a 
current is applied which will move the DNA fragments. Since DNA is negatively 
charged, it will migrate towards the positive electrode, colored red. By adding ethidium 
bromide, a fluorescent dye used for staining nucleic acids, the distance DNA has 
migrated can be seen. This dye intercalates between the bases of DNA. After the samples 
have run the length of the gel, the gel is placed under fluorescent light and the DNA is 
seen as dark bands against a gray background. 
 
Immunoprecipitation  
 HEK-293 cells in 100-mm dishes were transiently transfected with a total of 5 μg of 
plasmid DNA (the blank vector pcDNA3 was used as filler DNA in single transfections). After 
48 hours, the cells were washed with cold PBS and lysed in RIPA buffer (2.5 M NaCl, 0.5 M 
Tris pH 7.4, 0.5 M EDTA, 10% v/v Triton X-100, 1 mM PMSF and 0.2 mM Na3VO4) at 4 °C. 
Cell lysates were pre-cleared with Protein G beads, and were incubated with 1 μg of BCA2 
(rabbit) antibody for 21 hours. After incubation, the beads were collected by centrifugation, 
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washed with cold RIPA buffer and re-suspended in sample buffer. For Western blotting of 
immunoprecipitates, SUMO 2/3, UBC9 and BCA2 (Goat) was used as primary antibodies at 
1:1000 dilution. HRP-conjugated anti-Goat IgG or anti-mouse IgG antibodies were used as 





 In order to predict the SUMO binding position on the BCA2 protein sequence, 
SUMOplot analysis program was used and the results of this analysis are shown in Figure 1. 
Based on this analysis, Lys32 is the possible SUMO binding site for the BCA2 protein which 
scored 0.5 while the remaining 5 lysines scored negative values (data not shown), suggesting 
only K32 could undergo SUMO ligation.  
 
 
Figure 1: Predicted SUMO binding sites for BCA2 
 
 
  AEASAAGAD SGAAVAAHRF FCHFCKGEVS PKLPEYICPR CESGFIEEVT  
  DSSFLGGGG SRIDNTTTTH FAELWGHLDH TMFFQDFRPF LSSSPLDQDN  
   NERGHQTH TDFWGARPPR LPLGRRYRSR GSSRPDRSPA IEGILQHIFA  
  FFANSAIPG SPHPFSWSGM LHSNPGDYAW GQTGLDAIVT QLLGQLENTG  
   PADKEKIT SLPTVTVTQE QVDMGLECPV CKEDYTVEEE VRQLPCNHFF  
  SSCIVPWLE LHDTCPVCRK SLNGEDSTRQ SQSTEASASN RFSNDSQLHD  
   RWTF 
 
No. Pos. Group Score 
1 K32 KGEVS PKLP EYICP 0.50 
Figure 1: This shows a predicted binding site of BCA2 for SUMO proteins. 
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 In order to study the role of BCA2 in the SUMOylation process, SUMOylation of BCA2 
in vitro using SUMO-proteins was done using SUMO E1 and Ubc9 (Figure 2). As shown in 
Figure 2, a high molecular band was detected when WT BCA2 and a His- and GST-tagged 
SUMO 2/3 protein was used. Both of these tags were used to purify the SUMO proteins. Also, 
no bands were seen when RING BCA2 (mutant form of BCA2 which is ligase dead) was used 
with Sumo2/3 with either His Tag or GST Tag. Therefore, this data shows that SUMO 2/3 might 
be involved in the SUMOylation of WT BCA2. SUMO 1 was also tested and no high molecular 
weight bands were found (data not shown), further indicating that BCA2 might be  associated 
with only SUMO 2/3.    








   
Figure 2: WT BCA2 and the RING mutants were tested for SUMOylation in vitro using SUMO 
E1 and Ubc9 in the presence of ATP. 
 
 After assessing that BCA2 and SUMO 2/3 might interact with each other, 
immunoflourescence experiments were carried out in order to test if these proteins co-localize 
with each other within the cells. Immunoflourescence staining of BCA2 in MCF7 cells was 
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performed and these images were then captured using a Leica DM5500 microscope and 
Improvision software with a Retiga camera (Figure 3). 4', 6-diamidino-2-phenylindole (DAPI) 
was used in order to stain nuclei of the fixed cells. BCA2 was stained red and SUMO 2/3 stained 
green. All three stains were then merged in order to see overlap. As can be seen from the 
enlarged Figure 3, the blue arrows indicate overlap of BCA2 and SUMO 2/3. This data shows 
the co-localization of BCA2 and SUMO 2/3 in the nucleus of MCF7 cells, suggesting a possible 
interaction found using in vitro sumoylation (Figure 2). 
 
Figure 3: Co-localization of BCA2 and SUMO2/3 in the nucleus. 
  


















Figure 3: MCF7 cells immunoflourescence staining. BCA2 is stained red and SUMO 2/3 green. 
Co-localization of BCA2 (red) and SUMO 2/3 (green) in the nuclei (merge, blue arrows indicate 
the exact places of co-localization). 
 enlarged 






In order to identify the possible interaction of BCA2 and SUMO2/3, we purified the 
plasmid DNA from the bacterial cell cultures. These plasmids were a generous gift from Dr. 
Xiang Dong Zhang. After purification, the DNA of each colony was run on an agarose gel, 
(Figure 4).  




Figure 4: Agarose Gel of SUMO 1/2 and 3, colonies 1 and 2.  
  
 These plasmids were then used for transfection into HEK293T cells and for 
immunoprecipitation experiments. Immunoprecipitation is a technique where a protein antigen is 
precipitated out of solution using an antibody that binds specifically to that antigen. The antibody 
used was BCA2 (rabbit) and for the Western blot SUMO 2/3, BCA2 (Goat), and Ubc9 were used. 
As can be seen from Figure 5, the initial input contained a large amount of SUMO 2/3; when it 
was pulled down with BCA2, a clear signal was given in the Western blot, indicating that there is 
an association between BCA2 and SUMO 2/3. When this IP was probed for the Ubc9 signal, is 
strong signal showed up in the input as well as with pulldown with BCA2, which proves the 
previously established association between BCA2 and UBC9. Even though this is preliminary 
SUMO    SUMO    SUMO     SUMO 
1/2 - 1     1/2 - 2     3 - 1         3 -2  
 
6 kb 
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data, further confirmation of association between BCA2 and SUMO2/3 interaction should be 
validated using IgG controls for immunoprecipitation experiments. 
 




























 In order to study the role of BCA2 in the SUMOylation process, SUMO binding sites 
were predicted. From these bioinformatics analysis, K32 of BCA2 is the possible SUMO binding 
site. SUMOylation of BCA2 in vitro using SUMO-specific proteins was done using SUMO E1 
IP: anti BCA2 (Rabbit) 
WB: anti SUMO2/3 
WB: anti BCA2 (Goat) 
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and Ubc9. By using His Tag and GST tagged SUMO2/3 with WT BCA2 and RING BCA2, a 
possible SUMOylation between BCA2 and SUMO 2/3 were found. The dark bands, associated 
with BCA2 related SUMOylation, were only visible with WT BCA2 and not with RING BCA2. 
High molecular weight SUMO bands were seen for wild type BCA2 but not RING BCA2. This 
suggests that there is a correlation between BCA2 and SUMO 2 and 3, and this correlation is 
only present with SUMO 2/3 specific antibodies with the wild type BCA2 and not RING BCA2.  
 Furthermore, in order to detect possible protein-protein association, immunoflourescence 
staining of MCF7 cells were performed. This type of staining colors the areas the proteins are 
most prevalent in within the cells. BCA2 was stained red and SUMO 2/3 was green. By merging 
the three images (Figure 3) areas of overlap appear which designate places where an association 
between BCA2 and SUMO 2/3 is likely. It is clear that this overlap occurs within the nuclei of 
MCF7 cells, as indicated by the blue arrows. The co-localization of BCA2 and SUMO 2/3 show 
a possible interaction between them.  
After preparing and purifying the plasmids, I ran an agarose gel in order to detect the 
amount of DNA in my samples of SUMO1 and 2/3. These plasmids were used for further 
transfection experiments. 
Further experimentation of BCA2 and SUMO 2/3 performed was immunoprecipitation 
using the BCA2 antibody from rabbit to probe for SUMO 2/3, Ubc9 and BCA2 from goat. The 
Western blot experiment showed that a large amount of free SUMO 2/3 is seen in the input and 
there is a strong signal when it is pulled down with BCA2. This further confirms what was found 
in in vitro SUMOylation of BCA2 (Figure 2) and immunoflourescence imaging of MCF7 cells 
(Figure 3): there is an association between BCA2 and SUMO 2/3. Furthermore, the 
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immunoprecipitation data supports the findings of previous studies, which have established an 
association between BCA2 and Ubc9. Since there was a strong signal for Ubc9 in the Western 
blot after pulldown from BCA2, this indicates that BCA2 does interact with Ubc9 in the 
SUMOylation process and this is specifically related to SUMO 2/3. These results are very 
preliminary and with further studies and trials, better results are possible.  
 
Conclusion 
 With the increasing prevalence of cancer, especially breast cancer, treatment is vitally 
important to stop the continuous growth of the cancerous tumors. However, in order to fully treat 
a patient, a complete understanding of the cancer is needed to effectively target the correct 
proteins or molecules that are part of the mechanism. For this reason, it is quite a feat to create a 
drug that accomplishes this since the human body is so diverse and complex with each small 
interaction having monumental effects. 
 One aspect for understanding tumor growth is SUMOylation, which uses SUMO proteins 
in order to preserve protein homeostasis. SUMO proteins could interact with an E3 ligase which 
helps them attach to the target protein for modification. BCA2 is an E3 ligase and is found to be 
co-expressed with estrogen receptors (ER). Estrogen, the primary hormone in women, is 
necessary for breast tissue development and regulates the proliferation of tissues that express ER. 
ER has SUMO-attachment sites and it undergoes SUMOylation when activated. Therefore, this 
study was conducted in order to reveal the association between BCA2 and SUMOylation of 
target proteins involved in breast cancer.  
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 In order to find that association, in vitro SUMOylation of BCA2 was performed using 
Ubc9, a known E2 ligase, and SUMO E1, as well as immunoflourescence staining, plasmid 
purification, and immunoprecipitation. From these results it was revealed that BCA2 might 
interact with SUMO 2 and 3 in the SUMOylation pathway. Since BCA2 is highly expressed in 
breast cancers, its regulation and degradation could prove to be a vital aspect in finding new 
treatment options and drugs for battling breast cancer.  
 Even though an association between BCA2 and SUMO 2 and 3 has been found through 
this study, further experimentation in this mechanism will be needed in order to fully understand 
the implications behind this and other processes that are closely linked with breast cancer in 
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